Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Is Precision Medicine an Oxymoron?

Eckhardt SG, Lieu C.

JAMA Oncol. 2018 Nov 8. doi: 10.1001/jamaoncol.2018.5099. [Epub ahead of print] No abstract available.

PMID:
30419105
2.

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0315. doi: 10.1634/theoncologist.2018-0315. [Epub ahead of print]

PMID:
30139840
3.

Vaginal Angiomyofibroblastoma: A Case Report and Review of Diagnostic Imaging.

Eckhardt S, Rolston R, Palmer S, Ozel B.

Case Rep Obstet Gynecol. 2018 Jul 15;2018:7397121. doi: 10.1155/2018/7397121. eCollection 2018.

4.

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.

Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD.

Breast Cancer Res. 2018 Aug 2;20(1):82. doi: 10.1186/s13058-018-1014-y.

5.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.

Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S.

Anticancer Drugs. 2018 Oct;29(9):827-838. doi: 10.1097/CAD.0000000000000673.

6.

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.

Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH.

Cancer Res. 2018 Sep 15;78(18):5398-5407. doi: 10.1158/0008-5472.CAN-18-0316. Epub 2018 Jul 24.

PMID:
30042150
7.

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.

Scott AJ, Arcaroli JJ, Bagby SM, Yahn R, Huber KM, Serkova NJ, Nguyen A, Kim J, Thorburn A, Vogel J, Quackenbush KS, Capasso A, Schreiber A, Blatchford P, Klauck PJ, Pitts TM, Eckhardt SG, Messersmith WA.

Mol Cancer Ther. 2018 Oct;17(10):2112-2122. doi: 10.1158/1535-7163.MCT-17-0131. Epub 2018 Jul 19.

PMID:
30026382
8.

Lead pollution recorded in Greenland ice indicates European emissions tracked plagues, wars, and imperial expansion during antiquity.

McConnell JR, Wilson AI, Stohl A, Arienzo MM, Chellman NJ, Eckhardt S, Thompson EM, Pollard AM, Steffensen JP.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):5726-5731. doi: 10.1073/pnas.1721818115. Epub 2018 May 14.

PMID:
29760088
9.

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM.

BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z.

10.

Trends in single women with malignancy of the uterine cervix in United States.

Machida H, Blake EA, Eckhardt SE, Takiuchi T, Grubbs BH, Mikami M, Roman LD, Matsuo K.

J Gynecol Oncol. 2018 Mar;29(2):e24. doi: 10.3802/jgo.2018.29.e24. Epub 2017 Dec 27.

11.

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.

Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, Schreiber A, Messersmith WA, Devaraj KM, Blatchford P, Eckhardt SG, Cadogan EB, Hughes GD, Smith A, Pitts TM, Arcaroli JJ.

Oncotarget. 2017 Dec 5;8(67):110904-110913. doi: 10.18632/oncotarget.22920. eCollection 2017 Dec 19.

12.

Intrauterine Manipulator Use During Minimally Invasive Hysterectomy and Risk of Lymphovascular Space Invasion in Endometrial Cancer.

Machida H, Hom MS, Adams CL, Eckhardt SE, Garcia-Sayre J, Mikami M, Matsuo K.

Int J Gynecol Cancer. 2018 Feb;28(2):208-219. doi: 10.1097/IGC.0000000000001181.

PMID:
29324541
13.

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.

Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA.

PLoS One. 2017 Nov 1;12(11):e0187173. doi: 10.1371/journal.pone.0187173. eCollection 2017.

14.

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.

Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.

15.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
16.

Low concentrations of persistent organic pollutants (POPs) in air at Cape Verde.

Nøst TH, Halse AK, Schlabach M, Bäcklund A, Eckhardt S, Breivik K.

Sci Total Environ. 2018 Jan 15;612:129-137. doi: 10.1016/j.scitotenv.2017.08.217. Epub 2017 Sep 1.

17.

Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells.

Williams CM, Schonnesen AA, Zhang SQ, Ma KY, He C, Yamamoto T, Eckhardt SG, Klebanoff CA, Jiang N.

Front Immunol. 2017 Jul 28;8:894. doi: 10.3389/fimmu.2017.00894. eCollection 2017.

18.

Single Marital Status and Infectious Mortality in Women With Cervical Cancer in the United States.

Machida H, Eckhardt SE, Castaneda AV, Blake EA, Pham HQ, Roman LD, Matsuo K.

Int J Gynecol Cancer. 2017 Oct;27(8):1737-1746. doi: 10.1097/IGC.0000000000001068.

PMID:
28704326
19.

Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response.

Zhang C, Liu Z, Bunker E, Ramirez A, Lee S, Peng Y, Tan AC, Eckhardt SG, Chapnick DA, Liu X.

J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.

20.

A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.

Knoll J, Baghy K, Eckhardt S, Ferdinandy P, Garami M, Harsing LG Jr, Hauser P, Mervai Z, Pocza T, Schaff Z, Schuler D, Miklya I.

Life Sci. 2017 Aug 1;182:57-64. doi: 10.1016/j.lfs.2017.06.010. Epub 2017 Jun 13.

PMID:
28623006
21.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

Oncologist. 2017 Sep;22(9):1024-e89. doi: 10.1634/theoncologist.2017-0175. Epub 2017 Jun 7.

22.

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.

Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR.

Front Oncol. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094. eCollection 2017.

23.

Constraints on oceanic methane emissions west of Svalbard from atmospheric in situ measurements and Lagrangian transport modeling.

Pisso I, Myhre CL, Platt SM, Eckhardt S, Hermansen O, Schmidbauer N, Mienert J, Vadakkepuliyambatta S, Bauguitte S, Pitt J, Allen G, Bower KN, O'Shea S, Gallagher MW, Percival CJ, Pyle J, Cain M, Stohl A.

J Geophys Res Atmos. 2016 Dec 16;121(23):14188-14200. doi: 10.1002/2016JD025590. Epub 2016 Dec 10.

24.

Black Carbon Sources Constrained by Observations in the Russian High Arctic.

Popovicheva OB, Evangeliou N, Eleftheriadis K, Kalogridis AC, Sitnikov N, Eckhardt S, Stohl A.

Environ Sci Technol. 2017 Apr 4;51(7):3871-3879. doi: 10.1021/acs.est.6b05832. Epub 2017 Mar 15.

PMID:
28234491
25.

Siberian Arctic black carbon sources constrained by model and observation.

Winiger P, Andersson A, Eckhardt S, Stohl A, Semiletov IP, Dudarev OV, Charkin A, Shakhova N, Klimont Z, Heyes C, Gustafsson Ö.

Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1054-E1061. doi: 10.1073/pnas.1613401114. Epub 2017 Jan 30.

26.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

27.

Outcomes of an inpatient refeeding protocol in youth with Anorexia Nervosa and atypical Anorexia Nervosa at Children's Hospitals and Clinics of Minnesota.

Smith K, Lesser J, Brandenburg B, Lesser A, Cici J, Juenneman R, Beadle A, Eckhardt S, Lantz E, Lock J, Le Grange D.

J Eat Disord. 2016 Dec 19;4:35. doi: 10.1186/s40337-016-0124-0. eCollection 2016.

28.

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).

Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG.

Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25.

29.

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.

Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J.

J Vis Exp. 2016 Sep 30;(115). doi: 10.3791/54393.

30.

The sources of atmospheric black carbon at a European gateway to the Arctic.

Winiger P, Andersson A, Eckhardt S, Stohl A, Gustafsson Ö.

Nat Commun. 2016 Sep 15;7:12776. doi: 10.1038/ncomms12776.

31.

[Systemic therapy of breast cancer: practice guideline].

Horváth Z, Boér K, Dank M, Kahán Z, Kocsis J, Kövér E, Pajkos G, Pikó B, Rubovszky G, Eckhardt S.

Magy Onkol. 2016 Sep;60(3):241-57. Epub 2016 Jul 14. Review. Hungarian.

32.

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.

Serkova NJ, Eckhardt SG.

Front Oncol. 2016 Jul 15;6:152. doi: 10.3389/fonc.2016.00152. eCollection 2016. Review.

33.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

34.

Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.

Eckhardt S, Hoffmann S, Damanakis AI, Di Fazio P, Pfestroff A, Luster M, Wunderlich A, Bartsch DK.

Int J Surg Case Rep. 2016;25:174-8. doi: 10.1016/j.ijscr.2016.06.013. Epub 2016 Jun 16.

35.

Robotic-Assisted Approach Improves Vessel Preservation in Spleen-Preserving Distal Pancreatectomy.

Eckhardt S, Schicker C, Maurer E, Fendrich V, Bartsch DK.

Dig Surg. 2016;33(5):406-13. doi: 10.1159/000444269. Epub 2016 May 4.

PMID:
27160088
36.

Laser microstructured metal thin films as promising alternative for indium based transparent electrodes.

Eckhardt S, Siebold M, Lasagni AF.

Opt Express. 2016 Mar 21;24(6):A553-68. doi: 10.1364/OE.24.00A553.

PMID:
27136876
37.

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.

Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, Nguyen A, Gao D, Blatchford P, Capasso A, Schuller AG, Eckhardt SG, Arcaroli JJ.

Oncotarget. 2016 May 10;7(19):28273-85. doi: 10.18632/oncotarget.8626.

38.

MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5.

Damanakis AI, Eckhardt S, Wunderlich A, Roth S, Wissniowski TT, Bartsch DK, Di Fazio P.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1213-20. doi: 10.1007/s00432-016-2138-z. Epub 2016 Mar 9.

PMID:
26960757
39.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.

40.

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.

Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S.

Invest New Drugs. 2016 Apr;34(2):176-83. doi: 10.1007/s10637-015-0316-5. Epub 2015 Dec 30.

41.

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.

Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt SG, Heasley LE, Kang J, Tan AC.

BMC Genomics. 2015;16 Suppl 12:S2. doi: 10.1186/1471-2164-16-S12-S2. Epub 2015 Dec 9.

42.

The changing landscape of phase I trials in oncology.

Wong KM, Capasso A, Eckhardt SG.

Nat Rev Clin Oncol. 2016 Feb;13(2):106-17. doi: 10.1038/nrclinonc.2015.194. Epub 2015 Nov 10. Review.

PMID:
26552953
43.

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.

Oncotarget. 2015 Oct 27;6(33):34561-72. doi: 10.18632/oncotarget.5949.

44.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG.

Front Pharmacol. 2015 Jun 16;6:120. doi: 10.3389/fphar.2015.00120. eCollection 2015.

45.

The changing landscape of phase I trials in oncology.

Wong KM, Capasso A, Eckhardt SG.

Am Soc Clin Oncol Educ Book. 2015:3-8. doi: 10.14694/EdBook_AM.2015.35.3. Review. No abstract available.

46.

[Transaxillary robot-assisted thyroidectomy: First experiences with a new operation technique].

Eckhardt S, Maurer E, Fendrich V, Bartsch DK.

Chirurg. 2015 Oct;86(10):976-82. doi: 10.1007/s00104-015-0008-x. German.

PMID:
25971612
47.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR.

Mol Cancer Ther. 2015 May;14(5):1117-29. doi: 10.1158/1535-7163.MCT-14-0538-T. Epub 2015 Mar 10.

48.

Electron transfer in peptides: on the formation of silver nanoparticles.

Kracht S, Messerer M, Lang M, Eckhardt S, Lauz M, Grobéty B, Fromm KM, Giese B.

Angew Chem Int Ed Engl. 2015 Mar 2;54(10):2912-6. doi: 10.1002/anie.201410618. Epub 2015 Feb 6.

PMID:
25663127
49.

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.

Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW.

Clin Cancer Res. 2015 Mar 1;21(5):1002-9. doi: 10.1158/1078-0432.CCR-14-1234. Epub 2014 Dec 12.

50.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.

PLoS One. 2014 Nov 17;9(11):e113037. doi: 10.1371/journal.pone.0113037. eCollection 2014.

Supplemental Content

Loading ...
Support Center